Cargando…

Update on the clinical utility of an RNA interference-based treatment: focus on Patisiran

RNA interference (RNAi) is a naturally existing endogenous mechanism for post-transcriptional gene regulation, nowadays commonly utilized for functional characterization of genes and development of potential treatment strategies for diseases. RNAi-based studies for therapy, after being examined for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rizk, Malak, Tüzmen, Şükrü
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689029/ https://www.ncbi.nlm.nih.gov/pubmed/29184431 http://dx.doi.org/10.2147/PGPM.S87945

Ejemplares similares

Pharmacokinetics of Patisiran, the First Approved RNA Interference Therapy in Patients With Hereditary Transthyretin‐Mediated Amyloidosis
por: Zhang, Xiaoping, et al.
Publicado: (2019)

A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis
por: Urits, Ivan, et al.
Publicado: (2020)

Practical Guidance for the Use of Patisiran in the Management of Polyneuropathy in Hereditary Transthyretin-Mediated Amyloidosis
por: Dixon, Stacy, et al.
Publicado: (2023)

Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs
por: Suzuki, Yuta, et al.
Publicado: (2021)

Correction to: A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis
por: Urits, Ivan, et al.
Publicado: (2021)

Patisiran treatment in patients with hereditary transthyretin‐mediated amyloidosis with polyneuropathy after liver transplantation
por: Schmidt, Hartmut H., et al.
Publicado: (2022)

Patisiran in hATTR Amyloidosis: Six-Month Latency Period before Efficacy
por: Gentile, Luca, et al.
Publicado: (2021)

Italian Real-Life Experience of Patients with Hereditary Transthyretin Amyloidosis Treated with Patisiran
por: Di Stefano, Vincenzo, et al.
Publicado: (2022)

Human SNPs resulting in premature stop codons and protein truncation
por: Savas, Sevtap, et al.
Publicado: (2006)

Clinical improvement after change of therapy from tafamidis to patisiran in progressive TTR amyloidosis post-liver transplantation
por: Bulinski, Catherine, et al.
Publicado: (2022)

Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study
por: Suhr, Ole B, et al.
Publicado: (2015)

Phase 2 open-label extention (OLE) study of patisiran, an investigational siRNA agent for familial amyloidotic polyneuropathy (FAP)
por: Adams, David, et al.
Publicado: (2015)

A comparative analysis of international health technology assessments for novel gene silencing therapies: patisiran and inotersen
por: Iannazzo, Sergio
Publicado: (2021)

Deep brain stimulation, lesioning, focused ultrasound: update on utility
por: Reddy, Akshay, et al.
Publicado: (2023)

A retrospective survey of patients with hereditary transthyretin-mediated (hATTR) amyloidosis treated with patisiran in real-world clinical practice in Belgium
por: De Bleecker, Jan L., et al.
Publicado: (2023)

Patisiran Enhances Muscle Mass after Nine Months of Treatment in ATTRv Amyloidosis: A Study with Bioelectrical Impedance Analysis and Handgrip Strength
por: Di Stefano, Vincenzo, et al.
Publicado: (2022)

A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis
por: Coelho, Teresa, et al.
Publicado: (2020)

Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy
por: Adams, David, et al.
Publicado: (2017)

Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis
por: González-Duarte, Alejandra, et al.
Publicado: (2019)

Vial Sharing of High-Cost Drugs to Decrease Leftovers and Costs: A Retrospective Observational Study on Patisiran Administration in Bologna, Italy
por: Cozzio, Margherita, et al.
Publicado: (2023)

Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension
por: Ramani, Gautam V, et al.
Publicado: (2010)

Clinical trial update: focus on the ONTARGET study
por: Fitchett, David
Publicado: (2007)

Update on the treatment of disseminated fusariosis: Focus on voriconazole
por: Stanzani, Marta, et al.
Publicado: (2007)

Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure‐Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin‐Mediated (hATTR) Amyloidosis
por: Zhang, Xiaoping, et al.
Publicado: (2019)

Correction to: Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis
por: González-Duarte, Alejandra, et al.
Publicado: (2020)

Vernal Keratoconjunctivitis: an update focused on clinical grading system
por: Zicari, A. M., et al.
Publicado: (2019)

Hormone Immunoassay Interference: A 2021 Update
por: Ghazal, Khaldoun, et al.
Publicado: (2022)

Update on Treatment Guideline in Fibromyalgia Syndrome with Focus on Pharmacology
por: Kia, Sanam, et al.
Publicado: (2017)

Update and developments in the treatment of glioblastoma multiforme – focus on bevacizumab
por: Wagle, Naveed, et al.
Publicado: (2010)

Update on the clinical utility and optimal use of cefditoren
por: Barberán, José, et al.
Publicado: (2012)

Clinical utility of circulating tumor cells: an update
por: Vasseur, Antoine, et al.
Publicado: (2020)

An update on clinical utility of rilpivirine in the management of HIV infection in treatment-naïve patients
por: Putcharoen, Opass, et al.
Publicado: (2013)

RNA Interference in the Age of CRISPR: Will CRISPR Interfere with RNAi?
por: Unniyampurath, Unnikrishnan, et al.
Publicado: (2016)

RNA interference approaches for treatment of HIV-1 infection
por: Bobbin, Maggie L, et al.
Publicado: (2015)

Update on Hepatitis B Virus Infection: Focus on Treatment
por: Hadziyannis, Stephanos J.
Publicado: (2014)

Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat
por: Duvic, Madeleine, et al.
Publicado: (2007)

Herpes simplex virus interference with immunity: Focus on dendritic cells
por: MA, Farías, et al.
Publicado: (2021)

Immunotherapy for Urothelial Carcinoma: Focus on Clinical Utility of Nivolumab
por: Chiang, Ryan S, et al.
Publicado: (2022)

Progress in the clinical development and utilization of vision prostheses: an update
por: Brandli, Alice, et al.
Publicado: (2016)

An update in clinical utilization of photodynamic therapy for lung cancer
por: Wang, Kai, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_aoui3874ik67otsl7sqpf73unf